AI assistant
Xlife Sciences AG Regulatory Filings 2021
1041_rns_2021-06-16_210847aa-0e07-463a-ac86-8ebad6f2560f.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 0727C
Xlife Sciences AG
16 June 2021
Xlife Sciences AG: curasan AG and Xlife Sciences AG cooperate in the field of regenerative medicine
DGAP-Media
PRESS RELEASE
Zurich, Kleinostheim,
Xlife Sciences AG (XLS DE): curasan AG and Xlife Sciences AG cooperate in the field of regenerative medicine
curasan AG, a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery, and Xlife Sciences AG have initiated a collaboration in the field of regenerative medicine. Under the agreement it is intended to develop, produce, certify and market new products with a focus on the musculoskeletal area and tissue regeneration.
The main emphasis of the collaboration lies on the biologization of bone substitute materials and the development of an innovative manufacturing process. In this context, on the one hand, bone replacement products are to be manufactured using 3D printing processes by a project company of Xlife Sciences AG. The first series of tests have already yielded promising results. On the other hand, carrier materials are to be optimized for improved biofunctionality with substances that promote bone growth. For this purpose, new types of modalities, so-called exosomes, are introduced into the bone substitute material. Exosomes are bioactive nanoparticles that are secreted by stem cells or obtained from human platelets; these contain, among other molecules, growth factors and microRNAs.
"The cooperation with Xlife Sciences AG and its project companies gives curasan access to the most modern manufacturing processes as well as promising new therapies in musculoskeletal regeneration. In particular, the use of exosomes in conjunction with the tried and tested curasan products has enormous potential in tissue regeneration, "says Dirk Dembski, CEO of curasan AG. The Exosome Market recorded sales of approximately $ 174.04M in 2020 and is expected to experience a CAGR (Average Annual Growth Rate) of 27.89% over the forecast period (2021-2026) *
*Source: https://www.mordorintelligence.com/industry-reports/exosomes-market
About Xlife Sciences AGXlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch
About curasan AGcurasan develops, produces and markets biomaterials and medical devices for bone and tissue regeneration.
As a global technology leader in the future-oriented growth market of regenerative medicine, our company is specialized in biomimetic bone grafting materials mimicking biological structures for the use in orthopedics, traumatology, spine surgery and dental implantology.
Further information: https://www.curasan.de/en/company/about-us/
For media inquiries:Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Tel. +41 44 385 84 60, [email protected]
Andrea Weidner, Corporate Communications, curasan AG, Tel. +49 6027 40 900 51, [email protected]
For scientific inquiries:Dr. Frank Plöger, Chief Scientific Officer, Xlife Sciences AG, Tel. +41 44 385 84 62,
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Research/Technology
16.06.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Xlife Sciences AG |
| Klausstrasse 19 | |
| 8008 Zürich | |
| Switzerland | |
| Phone: | 0041 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| WKN: | A2PK6Z |
| Listed: | Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1208372 |
| End of News | DGAP Media |
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAEAKKKFLNFEEA